Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

d for the full year 2007.

General and administrative expenses in the fourth quarter of 2007 decreased to $1.8 million from $3.0 million in the year ago period resulting mainly from cost controls and less outsourced services. General and administrative expenses for the full year 2007 decreased to $6.1 million from $7.7 million for the full year 2006. This decrease was principally a result of legal and consulting expenses capitalized upon the completion of the IPO in 2007 compared to costs related to the unsuccessful IPO attempt in 2006 that were expensed.

On December 31, 2007, ImaRx had $12.9 million in cash, cash equivalents and investments, excluding $0.4 million in restricted cash, compared to $4.3 million in cash, cash equivalents and investments on December 31, 2006. The increase in the cash balance was primarily related to the $9.0 million sale of Abbokinase, net of discounts and fees, to two primary wholesale distributors and the $12.4 million in net proceeds received from the common stock offering in connection with the Company's July 2007 IPO. Assuming the tentative agreement with Abbott regarding the remaining balance of the $15.0 million note is executed and a strategic financing alternative for SonoLysis is achieved, the Company believes it will have sufficient cash resources for at least the next 12 months.

Additionally, in connection with the filing of its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2008, Ernst & Young LLP, the Company's independent registered public accounting firm, noted that the Company has recurring losses, which has resulted in a significant accumulated deficit at December 31, 2007. In addition, the Company has a significant note payable balance due on March 31, 2008. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern.

Conference Call and Webcast Information

Management will host a conferen
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DC....D., has stepped down from his position as a direc...r. Lewis advised the Company that his decision to ...commitments to new leadership positions. , , ...81118/NY46990LOGO ) , , Dr. Harold Koplewic...
(Date:12/4/2008)...e-FirstCall/ -- ExonHit Therapeutics S.A.,(Altern...ny, is pleased to,announce today that it has been...strial Property) during the last edition of its "T... "Since its inception, ExonHit consistently ma...f its intellectual property and in particular from...
(Date:12/3/2008).... 3 GlaxoSmithKline,(LS... a condition relating to a,pending lawsuit in the... of,the outstanding shares of common stock of Gen...1.30 per share in cash without interest and less a...ondition to the completion of the tender offer tha...
(Date:12/3/2008)...FirstCall/ -- Advanced Life Sciences Holdings,In.... Food and Drug,Administration (FDA) has accepted...A) for cethromycin, a novel once-a-day oral antibi...nity acquired pneumonia (CAP). The FDA has,estab...hat the anticipated,target action date of the cet...
Breaking Biology Technology:Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors 2ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI) 2ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI) 3GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia 2Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia 3
...rly known as Automating Peripherals, Inc., announc... API Software, Inc. is a provider of time and att...rces, productivity management, education tracking ...ations. , ,"After 20 years of evolving our produc...ting Peripherals, Inc., we decided we needed to up...
...loper of K-12 software solutions for special educa... announced their online, ASP software that streaml...ams (IEPs) and monitors the progress of children w...oduced in 16 Wisconsin school districts during 200... language therapists, physical therapists, psychol...
...oratories , a producer of active pharmaceutical in...rsenal Capital Partners . ,Arsenal, which targets ...ealthcare companies announced the acquisition, whi...in Waunakee, Wis., is the worlds largest independe...acture anticoagulants used in the prevention and t...
...gether to race the fastest cars they can build and..., scientists and technicians from Ohio State Unive...he goal is to win the $1 million dollar grand priz...nge . , ,The Defense Advanced Research Projects A...d advanced technology achievements that could lead...
Other Biology Technology:Oshkosh Truck Teams with OSU to Compete in DARPA Million Dollar Tech Derby 2Oshkosh Truck Teams with OSU to Compete in DARPA Million Dollar Tech Derby 3
(Date:12/4/2008)...INIA KEY, Fla. -- If you,re looking for bonefish f...about 321,000 to choose from, and that is down sli...due to increased participation among those who are...f Miami,s Rosenstiel School of Marine and Atmosphe...efish census, in conjunction with the conservation...
(Date:12/4/2008)...reat earthquakes and destructive tsunamis over the... of another large earthquake, warns an internation...published in the Dec. 4 issue of the journal Natu..., a magnitude 9.2 in December 2004, produced the m...emory. The cause of that calamity was the rupture...
(Date:12/3/2008)...d H. Jones, deputy executive director of the Inter...ergy Outlook 2008" Dec. 9 at Rice University,s Bak...ress such questions as: Is the world facing a supp...ent? What type of post-Kyoto policy framework migh...levels, and what impact might such a policy framew...
(Date:12/3/2008)...VILLE, Fla. The wild pea pod is big and heavy, wi...f its parent plant. , And yet, like a grounded t...t manages if it has a reasonable chance of escape... the world,s largest experimental landscape devote... or other natural areas have discovered the pea a...
Breaking Biology News(10 mins):Bonefish census reveals population holding steady 2September 2007 Sumatran earthquakes research findings 2September 2007 Sumatran earthquakes research findings 3'World Energy Outlook' to be presented at Rice University Dec. 9 2Rooted plants move mysteriously down greenways, scientists say 2Rooted plants move mysteriously down greenways, scientists say 3Streamline Health Solutions Inc Reports Third Quarter Results 6927 1Streamline Health Solutions Inc Reports Third Quarter Results 6927 2Streamline Health Solutions Inc Reports Third Quarter Results 6927 3Streamline Health Solutions Inc Reports Third Quarter Results 6927 4Streamline Health Solutions Inc Reports Third Quarter Results 6927 5Streamline Health Solutions Inc Reports Third Quarter Results 6927 6Streamline Health Solutions Inc Reports Third Quarter Results 6927 7Streamline Health Solutions Inc Reports Third Quarter Results 6927 8Streamline Health Solutions Inc Reports Third Quarter Results 6927 9Streamline Health Solutions Inc Reports Third Quarter Results 6927 10Streamline Health Solutions Inc Reports Third Quarter Results 6927 11Streamline Health Solutions Inc Reports Third Quarter Results 6927 12Millennium Biotechnologies Inc Launches SURGEX 28TM 29 the First Scientifically Validated Sports Nutritional Product Created from the Medical Market 1952 1Millennium Biotechnologies Inc Launches SURGEX 28TM 29 the First Scientifically Validated Sports Nutritional Product Created from the Medical Market 1952 2Millennium Biotechnologies Inc Launches SURGEX 28TM 29 the First Scientifically Validated Sports Nutritional Product Created from the Medical Market 1952 3Millennium Biotechnologies Inc Launches SURGEX 28TM 29 the First Scientifically Validated Sports Nutritional Product Created from the Medical Market 1952 4Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference 1950 1Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference 1950 2Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference 1950 3Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference 1948 1Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference 1948 2
...fect of the sun,s heat on weather balloons largely...tributed to a dispute over the existence of global...ale University and the National Oceanic and Atmosp...ublished in the journal Science, says that direct ...er balloon (radiosonde) probably explains the disc...
... of millions of locusts have, since Biblical times...ague" of major proportions, with the creatures des... now, it was thought that the directions of these ...inds. Now, Hebrew University of Jerusalem scientis...grasshoppers ?namely their polarization vision -- ...
...ersity of Alberta research team has discovered imp... effective treatments for pulmonary arterial hyper...e in the pulmonary arteries caused by uncontrolled...a disease that can lead to heart failure and death...that Survivin, a protein almost exclusively expres...
...chers at Harvard University have found evidence th... visual environment, dynamically adjusting its pro...g the commonplace. The scientists report in this w... that this principle of novelty-detection operates...irst for novelty begins in the eye itself," says M...
Other Biology News:Errors in the measurement of global warming corrected 2Locusts' built-in 'surface analysis' ability directs them to fly overland 2Researchers develop gene therapy to reverse pulmonary arterial hypertension 2Researchers develop gene therapy to reverse pulmonary arterial hypertension 3Retina adapts to seek the unexpected, ignore the commonplace 2
100 adhesive strips.
Homo sapiens palladin
Mouse P-Selectin/CD62P MAb (Clone 127933)
Molecular Biological Resources has extensive abilities cloning and expression of prokaryotic and eukaryotic proteins. Please contact lloconne@molbiores.com to discuss your project. Contact lloconne@
Biology Products: